Organization
Shanghai BDgene
7 clinical trials
Clinical trial
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-GlobinStatus: Recruiting, Estimated PCD: 2025-02-23
Clinical trial
Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1 Clinical Trail of the Safety and Efficacy of BD211 Intravenous Infusion for the Treatment of Transfusion-dependent β-thalassaemia PatientsStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Clinical Study on CRISPR/Cas9 Instantaneous Gene Editing Therapy to Primary Open-angle Glaucoma With Elevated Intraocular Pressure and MYOC Gene MutationStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Open-label, Single Dose, Phase Ⅰ Trial to Evaluate the Safety, Tolerability and Efficacy of BD111 in Patients With HSV-1 Stromal Keratitis in ChinaStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Multicenter, Single-blind, Single-dose, Randomized, Phase Ⅱa Trial to Evaluate the Safety, Tolerability and Efficacy of Intrastromal BD111 Gene Editing Therapy in Adults With HSV-1 Stromal KeratitisStatus: Not yet recruiting, Estimated PCD: 2025-12-01